Study details
Enrolling now
Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain
Wake Forest University Health Sciences
NCT IDNCT07053774ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
24
Study length
about 11 months
Ages
18–75
Locations
1 site in NC
About this study
Researchers are testing whether oxytocin helps reduce pain from heat. Participants will receive oxytocin or a placebo through the nose or vein, and rate their pain levels after each treatment. The trial will last about 329 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Intravenous oxytocin
- 2.Receive Intravenous placebo
- 3.Take Intranasal oxytocin
- +1 more
PhasePhase 2
DrugIntravenous oxytocin
Routeintranasal
Primary goalPain Scale Score - During Skin Heating
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
oxytocin (Hormone; causes uterine contractions)
Drug routes
intranasal, infusion
Endpoints
Primary: Pain Scale Score - During Skin Heating, Pain Scale Score - End of 5-minute Skin Heating
Secondary: Pain Scale Score - During Skin Heating